Bristol-Myers Squibb

Clovis Starts Ph III Trial with Combination of Rubraca and Opdivo in Advanced Ovarian Cancer
Clovis Starts Ph III Trial with Combination of Rubraca and Opdivo in Advanced Ovarian Cancer
CP Wire
Clovis Oncology
clinical trials
Bristol-Myers Squibb
Opdivo
ovarian cancer
Flag link:
Did a blockbuster drug make hundreds gamble compulsively? A legal fight may decide what science can’t confirm
Did a blockbuster drug make hundreds gamble compulsively? A legal fight may decide what science can’t confirm
Stat
Abilify
compulsive behavior
Bristol-Myers Squibb
Otsuka
Flag link:
Opdivo Approved in Europe for Additional Use in Melanoma Patients
Opdivo Approved in Europe for Additional Use in Melanoma Patients
CP Wire
Opdivdo
Bristol-Myers Squibb
melanoma
advanced melanoma
Europe
Flag link:
Opdivo Approved in Europe for Additional Use in Melanoma Patients
Opdivdo
Bristol-Myers Squibb
melanoma
advanced melanoma
Flag link:
BMS, Pfizer's fast-growing Eliquis is about to steamroll market-leader warfarin: executive
BMS, Pfizer's fast-growing Eliquis is about to steamroll market-leader warfarin: executive
Fierce Pharma
Pfizer
Bristol-Myers Squibb
JNJ
Eliquis
Xarelto
Warfarin
bloodthinners
Flag link:
After an epic battle of blockbusters, Merck leapfrogs Bristol-Myers to take the lead on PD-1/L1 market
After an epic battle of blockbusters, Merck leapfrogs Bristol-Myers to take the lead on PD-1/L1 market
Endpoints
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
anti-PD-L1
Flag link:
Bristol-Myers (BMY) Beats on Q2 Earnings, Raises Outlook
Bristol-Myers (BMY) Beats on Q2 Earnings, Raises Outlook
Yahoo/Zacks.com
earnings
Bristol-Myers Squibb
Flag link:
Bristol-Myers Squibb signs new development agreement for autoimmune disorders treatments
Bristol-Myers Squibb signs new development agreement for autoimmune disorders treatments
GoinPharma
autoimmune disease
Bristol-Myers Squibb
Flag link:
Bristol-Myers Squibb and Gritstone Oncology Announce Collaboration to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors
Bristol-Myers Squibb and Gritstone Oncology Announce Collaboration to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors
CP Wire
Bristol-Myers Squibb
Gritstone Oncology
Opdivo
Yervoy
GRANITE-001
cancer
Flag link:
Fresh Off Bristol Buyout, IFM Backers Raise $31M to Plot a Second Strike
Fresh Off Bristol Buyout, IFM Backers Raise $31M to Plot a Second Strike
Xconomy
IFM Therapeutics
Bristol-Myers Squibb
IFM Tre
Flag link:
Bristol-Myers Squibb and Gritstone Oncology Announce Collaboration to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors
Bristol-Myers Squibb
Gritstone Oncology
Opdivo
Flag link:
Opdivo Gains New Approval in Combination with Yervoy
Opdivo Gains New Approval in Combination with Yervoy
CP Wire
Opdivo
Yervoy
Bristol-Myers Squibb
metastatic colorectal cancer
Flag link:
Opdivo Gains New Approval in Combination with Yervoy
Bristol-Myers Squibb
Opdivdo
metastatic colorectal cancer
Flag link:
Bristol-Myers clears another hurdle in Merck lung cancer showdown — but big challenges remain
Bristol-Myers clears another hurdle in Merck lung cancer showdown — but big challenges remain
Endpoints
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
Flag link:
Bristol-Myers, AbbVie eye new use for myeloma drug Empliciti after phase 2 combo win
Bristol-Myers, AbbVie eye new use for myeloma drug Empliciti after phase 2 combo win
Fierce Pharma
Bristol-Myers Squibb
AbbVie
Empliciti
Multiple Myeloma
Flag link:
Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers
Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers
Motley Fool
NASH
liver disease
Viking Therapeutics
Madrigal Pharmaceuticals
Pfizer
Bristol-Myers Squibb
Gilead Sciences
Flag link:
Bristol-Myers wins the frenzied race to a first approval for a PD-1/L1 checkpoint in China as regulators hustle up a quick OK
Bristol-Myers wins the frenzied race to a first approval for a PD-1/L1 checkpoint in China as regulators hustle up a quick OK
Endpoints
Bristol-Myers Squibb
Opdivo
China
Flag link:
AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024
AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024
Fierce Pharma
Humira
AbbVie
Keytruda
Merck
Revlimid
Celgene
Opdivo
Bristol-Myers Squibb
Flag link:
ASCO18: 3 unanswered questions from oncology's largest conference
ASCO18: 3 unanswered questions from oncology's largest conference
Biopharma Dive
ASCO 2018
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
immunotherapy combinations
non-small cell lung cancer
Flag link:
ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?
ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?
Fierce Pharma
Bristol-Myers Squibb
biomarkers
ASCO 2018
Opdivo
Flag link:

Pages